Magnesio para Depresión

A 2023 meta-analysis (n=325) found that magnesium supplementation significantly reduced depression scores in adults with depressive disorder (SMD: -0.919, 95% CI: -1.443 to -0.396).

A 2013 meta-analysis (n=817) found that intrathecal magnesium 50-100 mg prolonged time to first analgesia request by at least 35 minutes as an adjuvant to spinal anesthesia.

A 2024 RCT (n=120) found that a combination of probiotics, magnesium orotate, and coenzyme 10 significantly reduced major depressive episodes and depressive symptoms over 8 weeks in adults with MDD.

A 2015 meta-analysis (n=19,137) found a potential association between hypomagnesaemia and depression, with a pooled RR of 1.34 (95% CI 1.01-1.79).

A 2016 meta-analysis (n=18655) found magnesium sulfate reduced risk of moderate to severe cerebral palsy (OR 0.61, 95% CI 0.42-0.89) in preterm infants exposed in utero, with no significant adverse effects on babies but maternal side effects.

A 2023 meta-analysis (n=4049) found that magnesium supplementation significantly improved depressive status (SMD=0.16, p=0.03).

A 2018 RCT (n=264) found that magnesium plus vitamin B6 was not superior to magnesium alone for stress reduction overall, but in those with severe/extremely severe stress, the combination provided 24% greater improvement at week 8.

A 2022 RCT (n=100) found Mg-Teadiola significantly reduced DASS-42 stress scores in chronically stressed healthy individuals compared to placebo, with small effect size (0.29).

A 2024 systematic review and meta-analysis (n=2813) found no statistically significant difference in efficacy or safety between 12-hour and 24-hour magnesium sulfate regimens for pre-eclampsia and eclampsia.

A 2023 systematic review (n=3020) found very low-certainty evidence that alternative magnesium sulphate regimens differ in effects on recurrence of convulsions or maternal death in women with pre-eclampsia or eclampsia.

A 2010 systematic review (n=2619) found that nutritional and herbal supplementation is effective for treating anxiety and anxiety-related conditions, with 71% of RCTs showing positive direction of evidence.

A 2018 meta-analysis (18 studies) found decreased serum magnesium levels in depression compared to controls.

A 2023 meta-analysis (n=28 studies) found that elemental metals including magnesium did not significantly reduce perinatal depression compared to placebo (SMD: -0.42; 95% CI: -1.05 to 0.21).

A 2023 meta-analysis of Chinese patients with depressive episodes found that salt valproate (sodium or magnesium) significantly reduced the switch rate to mania associated with antidepressant treatment, with odds ratios ranging from 0.11 to 0.18.

A 2017 meta-analysis of 17 studies found that dietary magnesium intake was inversely associated with depression risk (RR=0.81, 95% CI [0.70, 0.92]), with largest risk reduction at 320 mg/day.

A 2021 RCT (n not reported) studied magnesium with and without vitamin B6 in stressed adults with low magnesemia; depression was a secondary endpoint and showed improvement with magnesium + vitamin B6 compared to magnesium alone.

A 2020 systematic review (32 articles) found mixed results: 12 studies showed positive effects on depressive symptoms, 7 found correlation between low magnesium and depression, but no significant association with anxiety disorders; overall supplementation may be beneficial.

A 2017 systematic review (14 studies) found that combined magnesium and vitamin B6 supplementation reduced premenstrual anxiety but had no effect when used in isolation, and did not affect stress in women with dysmenorrhea.

A 2013 systematic review (n=27 studies) found that higher dietary magnesium intake was associated with lower depression symptoms, but results from blood and cerebrospinal fluid magnesium were inconclusive; oral magnesium supplementation may be effective but data are scarce.

A 2019 systematic review (11 primary studies, 1 RCT) found that magnesium and malic acid supplementation made little or no difference on pain and depressive symptoms in fibromyalgia patients.

A 2024 RCT (n=80) found that intraoperative magnesium sulphate administration was an independent predictor of reduced postoperative insomnia and pain in patients undergoing lumbar fixation.

A 2020 systematic review (n=20 articles) found that magnesium intake was associated with reduced depressive symptoms or depression.

A 2013 systematic review found conflicting but mainly positive evidence for n-3 and chromium in bipolar depression, and limited evidence that choline, magnesium, folate, and tryptophan may reduce manic symptoms.

A 2019 systematic review (18 RCTs) found limited procedure-specific evidence of analgesic effects for magnesium in laparoscopic sleeve gastrectomy.

A 2016 observational study (n=15,836) found no significant association between magnesium intake and depression incidence (HR=0.85, 95% CI 0.60-1.22 for highest vs lowest quintile).